Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

被引：7

作者：

Mailankody, Sham ^{[1
]}

Matous, Jeffrey, V ^{[2
]}

Liedtke, Michaela ^{[3
,4
]}

Sidana, Surbhi ^{[5
]}

Oluwole, Olalekan O. ^{[6
]}

Mohan, Meera ^{[7
]}

Cruz, Jose C. ^{[8
]}

Nath, Rajneesh ^{[9
]}

Anwer, Faiz ^{[10
]}

Rossi, Adriana ^{[11
]}

Htut, Myo ^{[12
]}

Malik, Shahbaz A. ^{[13
]}

Ghatta, Srinivas ^{[14
]}

Dillon, Myles ^{[14
]}

Ying, Wendy ^{[14
]}

Navale, Lynn ^{[14
]}

Karski, Erin E. ^{[14
]}

Balakumaran, Arun ^{[14
]}

Kumar, Shaji K. ^{[15
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA

[4] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA

[5] Stanford Univ, Sch Med, Dept Med, Div Blood & Marrow Transplantat & Cellular Therap, Stanford, CA USA

[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[7] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA

[8] Texas Transplant Inst, San Antonio, TX USA

[9] Banner MD Anderson Canc Ctr, Scottsdale, AZ USA

[10] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[11] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA

[12] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA

[13] St Davids South Austin Med Ctr, Austin, TX USA

[14] Allogene Therapeut, South San Francisco, CA USA

[15] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158231

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4620 / 4622

页数：3

共 50 条

[1] Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Mailankody, Sham
Liedtke, Michaela
Sidana, Surbhi
Matous, Jeffrey V.
Chhabra, Saurabh
Oluwole, Olalekan O.
Malik, Shahbaz A.
Kumar, Shaji
Nath, Rajneesh
Anwer, Faiz
Cruz, Jose Carlos
Jagannath, Sundar
Htut, Myo
Raje, Noopur S.
Siegel, David S.
Karski, Erin E.
Lovelace, Wade
Lourbakos, Afrodite
Nandakumar, Srinand Ponnathapura
Balakumaran, Arun
Hari, Parameswaran
BLOOD, 2021, 138
[2] Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
Mailankody, Sham
Matous, Jeffrey V.
Liedtke, Michaela
Sidana, Surbhi
Malik, Shahbaz
Nath, Rajneesh
Oluwole, Olalekan O.
Karski, Erin E.
Lovelace, Wade
Zhou, Xiangdong
Nandakumar, Srinand
Balakumaran, Arun
Hari, Parameswaran
BLOOD, 2020, 136
[3] ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Sommer, Cesar
Boldajipour, Bijan
Valton, Julien
Galetto, Roman
Bentley, Trevor
Sutton, Janette
Ni, Yajin
Leonard, Mark
Van Blarcom, Thomas
Smith, Julianne
Chaparro-Riggers, Javier
Sasu, Barbra
BLOOD, 2018, 132
[4] Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
Qu, Xiaoyan
An, Gang
Sui, Weiwei
Wang, Tingyu
Zhang, Xian
Yang, Junfang
Zhang, Yan
Zhang, Lu
Zhu, Judy
Huang, Jiaqi
Li, Jing
Zheng, Shirley
Zhu, Kevin
Lan, Liping
Chen, Shiyi
Humphries, Michael
Yao, Yihong
Zhou, Daobin
Lu, Peihua
Qiu, Lugui
Li, Jianyong
BLOOD, 2021, 138 : 1830 - +
[5] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Feng, Deming
Sun, Jian
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
[6] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
Arora, Sankalp
Giri, Smith
Godby, Kelly Nicole
Ravi, Gayathri
Costa, Luciano J.
Bal, Susan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
Zhang, Xiaohui
Ouyang, Chenxi
Sun, Guofeng
Liu, Hongfeng
Qi, Junyuan
Suo, Xiaohui
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
[8] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
Yao, Xin
Zhu, Shigui
Huang, Jiaqi
Qu, Xiaoyan
Zhu, Judy
Wei, Yutian
Lan, Liping
Lv, Xiaoteng
Wu, Junfeng
Wang, Rirfei
Yang, Dingzhu
Zheng, Chengxiao
Zhao, DiJun
Fan, Lei
Huang, Fei
Lu, Hua
Zhang, Chaocan
Chen, Cheng
Li, Yanfeng
Ren, Jiaqiang
Zhang, Li
Humphries, Michael
Li, Jianyong
Yao, Yihong
BLOOD, 2019, 134
[9] P-BCMA-ALLO1-a nonviral, allogeneic anti-BCMA CAR-T therapy with potent antitumor function for the treatment of multiple myeloma
Richter, Maximilian
Cranert, Stacey
Tan, Yening
Tong, Min
Domingo, Christine
Argus, Elvira
Ibitokou, Samad
Smith, Jenessa
Martin, Christopher
Wang, Xinxin
Barnett, Burton
Ostertag, Eric
Coronella, Julia
Shedlock, Devon
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[10] A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
Li, Chunrui
Cao, Wenyue
Que, Yimei
Wang, Qiuxiang
Xiao, Yi
Gu, Chaojiang
Wang, Di
Wang, Jue
Jiang, Lijun
Xu, Hao
Xu, Jinhuan
Zhou, Xiaoxi
Hong, Zhenya
Wang, Na
Huang, Liang
Zhang, Shangkun
Chen, Liting
Mao, Xia
Xiao, Min
Zhang, Wei
Meng, Li
Cao, Yang
Zhang, Tongcun
Li, Jian
Zhou, Jianfeng
CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (03):

← 1 2 3 4 5 →